溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展

doi:10.16352/j.issn.1001-6325.2022.04.019

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (4): 651-655.doi: 10.16352/j.issn.1001-6325.2022.04.019

溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展

甘兹颖¹, 唐慧^2*

1.昆明理工大学医学院; 2.昆明理工大学附属医院云南省消化内镜临床医学中心昆明市肿瘤分子与免疫防治重点实验室, 云南昆明 650032

收稿日期:2020-12-14 修回日期:2021-04-06 出版日期:2022-04-05 发布日期:2022-04-01
通讯作者: * htang1122@aliyun.com
基金资助:
国家自然科学基金(81460463);云南省科技厅-昆明医科大学联合基金[2019FE001(-173)],云南省消化内镜临床医学中心基金(2X2019-01-02);昆明市肿瘤分子与免疫重点实验室基金(2018-1-A-17334)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors

GAN Zi-ying¹, TANG Hui^2*

1. School of Medical, Kunming University of Science and Technology; 2. Yunnan Digestive Endoscopy Clinical Medical Center, Kunming Key Laboratory of Tumor Molecular & Immune Prevention, the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032,China

Received:2020-12-14 Revised:2021-04-06 Online:2022-04-05 Published:2022-04-01
Contact: * htang1122@aliyun.com

摘要/Abstract

摘要： 溶瘤病毒常以两种方式与程序性死亡受体1/程序性死亡受体-配体1(PD-1/PD-L1)为代表的免疫检查点抑制剂联合使用,一种为PD-1/PD-L1抑制剂联合基因重组修饰以及天然弱毒性的溶瘤病毒,另一种则是携带PD-1/PD-L1抗体基因的基因重组溶瘤病毒。

关键词: PD-1/PD-L1, 免疫检查点抑制剂, 溶瘤疗法

Abstract: Oncolytic viruses are often used in combination with immune checkpoint inhibitors represented in two ways by programmed cell death 1/programmed cell death-Ligand 1 (PD-1/PD-L1). One is oncolytic virus combined with PD-1/PD-L1 inhibitors, which is modified by gene recombination and natural weak toxicity, and another one is oncolytic virus with gene recombination carrying PD-1/PD-L1 antibody gene.

Key words: PD-1/PD-L1, immune checkpoint inhibitor, oncolytic therapy

中图分类号:

R730.51

甘兹颖, 唐慧. 溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展[J]. 基础医学与临床, 2022, 42(4): 651-655.

GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors[J]. Basic & Clinical Medicine, 2022, 42(4): 651-655.

参考文献

[1] Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018, 175: 313-326.
[2] Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies[J]. Annu Rev Med, 2014, 65: 185-202.
[3] Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies[J]. Cancer Cell, 2018, 33: 581-598.
[4] Vonderheide RH. The immune revolution: a case for priming, not checkpoint[J]. Cancer Cell, 2018, 33: 563-569.
[5] Vonderheide RH, Domchek SM, Clark AS. Immuno-therapy for breast cancer: What are we missing?[J]. Clin Cancer Res, 2017, 23: 2640-2646.
[6] Chen Q, Xu L, Du T, et al. Enhanced expression of PD-L1 on microglia after surgical brain injury exerts self-protection from inflammation and promotes neurological repair[J]. Neurochem Res, 2019, 44: 2470-2481.
[7] Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immun-otherapies[J]. Nat Rev Drug Discov, 2019, 18: 197-218.
[8] Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines[J]. Cancer Cell, 2018, 33: 599-605.
[9] Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy[J]. Nat Rev Immunol, 2018, 18: 498-513.
[10] Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy[J]. Cell, 2017, 170: 1109-1119.
[11] Sun F, Guo ZS, Gregory A, et al. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer[J]. J Immunother Cancer, 2020, 8: e000294. doi: 10.1136/jitc-2019-000294.
[12] Vijayakumar G, Palese P, Goff PH. Oncolytic newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma[J]. EBioMedicine, 2019, 49: 96-105.
[13] Liu Z, Ravindranathan R, Kalinski P, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy[J]. Nat Commun, 2017, 8: 14754. doi: 10.1038/ncomms14754.
[14] Smith HG, Mansfield D, Roulstone V, et al. PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma[J]. Clin Cancer Res, 2019, 25: 3443-3454.
[15] Chaurasiya S, Chen NG, Fong Y. Oncolytic viruses and immunity[J]. Curr Opin Immunol, 2018, 51: 83-90.
[16] 李冲, 王志平. 溶瘤腺病毒抗肿瘤策略研究进展[J]. 基础医学与临床, 2016, 36: 547-551.
[17] Harrington K, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment[J]. Nat Rev Drug Discov, 2019, 18: 689-706.
[18] Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, checkmate-143: the game is not over yet[J]. Oncotarget, 2017, 8: 91779-91794.
[19] Kim SS, Harford JB, Moghe M, et al. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma[J]. Int J Cancer, 2019, 145: 2535-2546.
[20] Passaro C, Alayo Q, De Laura I, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy[J]. Clin Cancer Res, 2019, 25: 290-299.
[21] Zhou G, Ni D, Yan R, et al. New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody[J]. J Clin Oncol, 2019, 37: e14250.doi:10.1158/1538-7445.AM2019-LB-078.

溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价